MX2021004741A - Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo. - Google Patents

Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.

Info

Publication number
MX2021004741A
MX2021004741A MX2021004741A MX2021004741A MX2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A
Authority
MX
Mexico
Prior art keywords
compound
same
aminopeptidase
inhibitors
pharmaceutical compositions
Prior art date
Application number
MX2021004741A
Other languages
English (en)
Inventor
Catherine Llorens-Cortes
Yannick Marc
Fabrice Balavoine
Delphine Compere
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of MX2021004741A publication Critical patent/MX2021004741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3264—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65306—Five-membered rings containing two nitrogen atoms
    • C07F9/65312—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención actual se refiere a un nuevo compuesto, a una composición que lo comprende, a métodos para preparar el compuesto y al uso de este compuesto en terapia. En particular, la invención actual se refiere a un compuesto que es útil en el tratamiento y prevención de hipertensión arterial primaria y secundaria, accidente cerebrovascular, isquemia miocárdica, insuficiencia cardíaca y renal, infarto de miocardio, enfermedad vascular periférica, proteinuria diabética, síndrome X y glaucoma.
MX2021004741A 2018-10-26 2019-10-25 Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo. MX2021004741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306396 2018-10-26
PCT/EP2019/079229 WO2020084131A1 (en) 2018-10-26 2019-10-25 Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
MX2021004741A true MX2021004741A (es) 2022-03-16

Family

ID=64267736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004741A MX2021004741A (es) 2018-10-26 2019-10-25 Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.

Country Status (15)

Country Link
US (1) US11192907B2 (es)
EP (1) EP3870591A1 (es)
JP (1) JP7051009B2 (es)
KR (1) KR102380042B1 (es)
CN (1) CN113166182A (es)
AR (1) AR116853A1 (es)
AU (1) AU2019365119B2 (es)
BR (1) BR112021007116A2 (es)
CA (1) CA3112851C (es)
EA (1) EA202191150A1 (es)
IL (1) IL282591B (es)
MX (1) MX2021004741A (es)
TW (1) TW202029962A (es)
WO (1) WO2020084131A1 (es)
ZA (1) ZA202103580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116854A1 (es) * 2018-10-26 2021-06-23 Quantum Genomics Derivados aminofosfínicos como inhibidores de aminopeptidasa a
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素－血管收縮素系統阻斷劑之醫藥組合物
CN115385789B (zh) * 2022-09-19 2024-06-04 安徽大学 一种4-氧代丁酸甲酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
ES2369256T3 (es) * 2000-06-26 2011-11-28 Helen Of Troy Limited Sistema de lámpara recargable.
AR058296A1 (es) * 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
US20080146524A1 (en) 2006-12-14 2008-06-19 Solvay Pharmaceuticals B.V. Selective inhibitors of neurotensin degrading enzymes
FR2934267B1 (fr) 2008-07-23 2010-08-13 Pharmaleads Derives aminophosphiniques utiles dans le traitement de la douleur
AR116854A1 (es) 2018-10-26 2021-06-23 Quantum Genomics Derivados aminofosfínicos como inhibidores de aminopeptidasa a

Also Published As

Publication number Publication date
IL282591B (en) 2022-08-01
KR20210079336A (ko) 2021-06-29
CA3112851C (en) 2023-01-24
IL282591A (en) 2021-06-30
CN113166182A (zh) 2021-07-23
ZA202103580B (en) 2022-08-31
AU2019365119B2 (en) 2021-07-29
JP7051009B2 (ja) 2022-04-08
JP2021535189A (ja) 2021-12-16
TW202029962A (zh) 2020-08-16
AU2019365119A1 (en) 2021-04-15
WO2020084131A1 (en) 2020-04-30
US20210309678A1 (en) 2021-10-07
EA202191150A1 (ru) 2021-07-15
AR116853A1 (es) 2021-06-23
KR102380042B1 (ko) 2022-03-28
US11192907B2 (en) 2021-12-07
BR112021007116A2 (pt) 2021-07-20
CA3112851A1 (en) 2020-04-30
EP3870591A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
MX2021004741A (es) Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
MX2024008551A (es) Terapias de combinacion.
MX2021004728A (es) Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
MY187899A (en) (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
MX2021011041A (es) Compuestos y composiciones que comprenden los mismos para tratar hipertension o fallo cardiaco.
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors